DCM
DAFNA Capital Management Portfolio holdings
AUM
$362M
This Quarter Return
+13.83%
1 Year Return
-0.48%
3 Year Return
+117.01%
5 Year Return
+181.93%
10 Year Return
+1,483.26%
AUM
$421M
AUM Growth
+$421M
(+25%)
Cap. Flow
+$56.4M
Cap. Flow
% of AUM
13.37%
Top 10 Holdings %
Top 10 Hldgs %
50.23%
Holding
96
New
22
Increased
24
Reduced
22
Closed
7
Top Buys
| 1 |
Nurix Therapeutics
NRIX
|
$9.52M |
| 2 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
$7.59M |
| 3 |
Revolution Medicines
RVMD
|
$5.91M |
| 4 |
Protalix BioTherapeutics
PLX
|
$5.37M |
| 5 |
Adicet Bio
ACET
|
$4.02M |
Top Sells
| 1 |
Cassava Sciences
SAVA
|
$3.07M |
| 2 |
CNST
Constellation Pharmaceuticals, Inc.
CNST
|
$2.9M |
| 3 |
AGTC
Applied Genetic Technologies Corporation
AGTC
|
$2.4M |
| 4 |
Neuronetics
STIM
|
$2.35M |
| 5 |
Neurocrine Biosciences
NBIX
|
$1.8M |
Sector Composition
| 1 | Healthcare | 90.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Stereotaxis
STXS
$261M
| $91.9M | 21.81% | 13,680,554 | – | – |
|
2
Fate Therapeutics
FATE
$120M
| $25.9M | 6.15% | 314,360 -20,000 | -6% | -$1.65M |
|
|
BPMC
3
DELISTED
Blueprint Medicines
BPMC
| $20.2M | 4.8% | 207,911 +1,000 | +0.5% | +$97.2K |
|
|
DRNA
4
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $15M | 3.57% | 587,756 | – | – |
|
|
SAGE
5
DELISTED
Sage Therapeutics
SAGE
| $13.6M | 3.22% | 181,306 | – | – |
|
|
MORF
6
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $11.5M | 2.72% | 181,467 +120,000 | +195% | +$7.59M |
|
|
7
Nurix Therapeutics
NRIX
$714M
| $9.52M | 2.26% | +306,320 | New | +$9.52M |
|
8
AtriCure
ATRC
$1.84B
| $8.42M | 2% | 128,529 -4,700 | -4% | -$308K |
|
|
AFMD
9
DELISTED
Affimed
AFMD
| $7.83M | 1.86% | 989,857 +115,500 | +13% | +$914K |
|
10
IDEAYA Biosciences
IDYA
$2.15B
| $7.79M | 1.85% | 331,661 | – | – |
|
11
DexCom
DXCM
$29.5B
| $7.6M | 1.8% | 21,138 | – | – |
|
12
Xenon Pharmaceuticals
XENE
$2.98B
| $7.28M | 1.73% | 406,535 +60,000 | +17% | +$1.07M |
|
13
ProQR Therapeutics
PRQR
$237M
| $7.27M | 1.73% | 1,100,000 -137,400 | -11% | -$908K |
|
|
14
Neurocrine Biosciences
NBIX
$13.8B
| $7.16M | 1.7% | 73,655 -18,553 | -20% | -$1.8M |
|
|
15
Revolution Medicines
RVMD
$7.1B
| $6.94M | 1.65% | 151,231 +128,731 | +572% | +$5.91M |
|
|
BHVN
16
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $6.4M | 1.52% | 93,600 +11,500 | +14% | +$786K |
|
17
iShares Biotechnology ETF
IBB
$5.6B
| $6.08M | 1.44% | 40,400 -7,000 | -15% | -$1.05M |
|
18
Galapagos
GLPG
$2.07B
| $5.8M | 1.37% | 75,175 -5,200 | -6% | -$401K |
|
|
KRTX
19
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $5.77M | 1.37% | 48,000 +31,332 | +188% | +$3.77M |
|
|
CSII
20
DELISTED
Cardiovascular Systems, Inc.
CSII
| $5.74M | 1.36% | 149,700 -1,500 | -1% | -$57.5K |
|
|
TVRD
21
Tvardi Therapeutics, Inc. Common Stock
TVRD
$281M
| $5.68M | 1.35% | 261,442 | – | – |
|
|
22
Protalix BioTherapeutics
PLX
$124M
| $5.37M | 1.28% | +1,204,825 | New | +$5.37M |
|
|
ARNA
23
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $5.32M | 1.26% | 76,715 -100 | -0.1% | -$6.94K |
|
|
24
Adicet Bio
ACET
$59.9M
| $5.04M | 1.2% | 385,077 +307,500 | +396% | +$4.02M |
|
|
AERI
25
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $4.93M | 1.17% | 275,840 -12,600 | -4% | -$225K |
|